Skip to main content

Sound Advice: November 3, 2021

Medicare 201 

Coverage of outpatient prescription drugs under Medicare Part D began on January 1, 2006.  Part D is an optional plan that is available to everyone enrolled in Medicare Part A and Part B.  There are numerous plans available and there are considerable differences in ongoing plan prices as well as drug costs.

Let’s begin with some basics.  One of the most important is the formulary, the list of prescription drugs (both name brand and generic) preferred by the health plan.  There are copays for those that are on the list.  For drugs not on the list, the patient may have to pay full price.  Formularies change annually and drugs that have been included in the formulary may switch from preferred to nonpreferred or be removed entirely.

Within the formulary there are different tiers for the drugs included.  Tier 1 is generic drugs, which have the lowest possible copayment.  Tier 2 includes brand-name drugs that do not have a generic option.  Tier 3 consists of nonpreferred, brand-name drugs that do have a generic option. Tier 4 includes nonpreferred brand-name drugs and some nonpreferred, high-cost generic drugs.  With Part D coverage, the copayment costs can range from just a few dollars to fairly hefty sums. 

In addition, there are preferred pharmacies.  A preferred pharmacy network is a group of pharmacies willing to give the plans a larger discount than those offered by other pharmacies.

That leads us to the next issue: the stages of coverage.

Stage 1 of Part D is when you pay the full cost of prescriptions until you meet the annual deductible, which may be as little as zero or much higher, depending on the plan selected. 

Stage 2 of Part D is when the plan pays for a portion of the prescription drug you purchase, as long as the drug is covered under the plan’s formulary.  The copay is determined by the tier level assigned to the drug.  This stage ends when the amount spent by you and your plan adds up to the coverage limit set by Medicare for that year.  The limit for 2022 is $4,430.

Stage 3 of Part D is known as the coverage gap (a.k.a., the donut hole) for those whose spending on prescription drugs has exceeded the Stage 2 limit.  When in Stage 3, participants will pay 25% of the plan’s cost for covered brand-name and generic drugs.  Stage 3 ends when the total spending for covered drugs reaches $7,050.  This number is the total of copays, yearly deductible, and what has been paid for drugs in the coverage gap.

Stage 4 of Part D is known as catastrophic coverage.  In this stage, the plan and the government pay for about 95% of the cost.  Participants in Stage 4 remain in this stage until the end of the coverage year. 

For more details, go to medicare.gov.

N. Russell Wayne, CFP®

Sound Asset Management Inc.

Weston, CT  06883

203-222-9370

www.soundasset.com

www.soundasset.blogspot.com

Any questions?  Please contact me at nrwayne@soundasset.com

Comments

Popular posts from this blog

Sound Advice: September 30, 2026

Now what? For many women, there comes a time when financial confusion reigns.   It may come after a spouse passes or a marriage goes off the rails.   It’s the same situation for women who never married. The questions are many.   The answers may be few.   Toward the top of the list of concerns is the issue of understanding.   Although there are always complex matters, it’s essential that all of the elements are clearly presented in a straightforward fashion.   There’s more.   Presentation is one thing, but comprehension is another. If there’s a question, it must be asked.   Clarity is the key.   Don’t just say I get it when you don’t.   And, it’s essential to grasp how each of the items fits in the overall situation. In the absence of understanding, no decisions will be made. Here are some of the most pressing questions? What’s the smart way to handle my investments? Where should I go for advice? A bank, stockbroker, attor...

Sound Advice: September 19, 2026

Is AI good news or bad news for investments? AI is potentially very good news for investors—but not automatically good news for every investment . The key distinction is between AI as an economic technology and AI stocks at today's prices . As of September 2026, there are compelling reasons for both optimism and caution: The bullish case: AI spending remains enormous. Gartner estimates global AI spending at $2.7 trillion in 2026 , up 49.5% year over year. If AI produces sustained productivity gains, corporate profits could expand well beyond the companies currently selling AI hardware. The valuation case: Investors have already priced in a lot of success. Valuations of major AI companies are elevated and expected long-term earnings growth is well above historical norms. The spending-risk case: The five largest hyperscalers are expected to spend more than $1 trillion on AI-related capital expendit...

Sound Advice: October 14, 2026

Why your adviser must be a fiduciary   You should insist that your financial adviser be a fiduciary because a fiduciary is legally obligated, when acting in a fiduciary capacity, to put your interests ahead of their own and manage conflicts of interest appropriately. Key reasons: Your interests come first. A fiduciary duty requires the adviser to act in your best interest rather than simply recommending something that is suitable or profitable for them. Fewer conflicts of interest. Some advisers can receive commissions, bonuses, or other compensation for recommending particular investments or insurance products. A fiduciary must address material conflicts rather than allowing them to drive the recommendation. Greater transparency. Fiduciary advisers generally have obligations concerning disclosure, fees, conflicts, and how they are compensated. That makes it easier for you to understand what you're actually paying. Better alignment over the long term. A good adviser sh...